Summerfield, J. A., Nagafuchi, Y., Sherlock, S., Cadafalch, J. & Scheuer, P. J. Hepatobiliary fibropolycystic diseases: A clinical and histological review of 51 patients. J. Hepatol. 2, 141 (1986).
Desmet, V. J. What is congenital hepatic fibrosis?. Histopathology 20, 465–477 (1992).
Madjov, R., Chervenkov, P., Madjova, V. & Balev, B. Caroli’s disease: Report of five cases and review of the literature. Hepatogastroenterology 52, 606–609 (2005).
Hoyer, P. F. Clinical manifestations of autosomal recessive polycystic kidney disease. Curr. Opin. Pediatr. 27, 186–192 (2015).
Todani, T., Watanabe, Y., Narusue, M., Tabuchi, K. & Okajima, K. Congenital bile duct cysts: Classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am. J. Surg. 134, 263–269 (1977).
Awasthi, A., Das, A., Srinivasan, R. & Joshi, K. Morphological and immunohistochemical analysis of ductal plate malformation: Correlation with fetal liver. Histopathology 45, 260–267 (2004).
Zhu, L., Zhao, G., Jia, C. F. & Li, Y. A case of congenital hepatic fibrosis associated with medullary sponge kidney: Radiologic and pathologic features. Gastroenterol. Res. 5, 63–66 (2012).
Wang, Z. X. et al. Clinical classification of Caroli’s disease: An analysis of 30 patients. HPB (Oxford) 17, 278–283 (2015).
Lee, S. H., Lee, T. Y., Jeong, J. H. & Cheon, Y. K. Clinical significance of the neutrophil–lymphocyte ratio as an early predictive marker for adverse outcomes in patients with acute cholangitis. Med. (Kaunas). 58, 255 (2022).
González-Ojeda, A. et al. Platelet count/spleen diameter ratio to predict oesophageal varices in Mexican patients with hepatic cirrhosis. World J. Gastroenterol. 20, 2079–2084 (2014).
Lewin, M. et al. Diffuse versus localised Caroli disease: a comparative MRCP study. AJR Am. J. Roentgenol. 216, 1530–1538 (2021).
Paquet, K. J. Prophylactic endoscopic sclerosing treatment of esophageal wall in varices: a prospective controlled trial. Endoscopy 14, 4–5 (1982).
Issar, P. & Issar, S. K. Caroli’s disease. Indian J. Gastroenterol. 33, 500 (2014).
Torra, R. et al. Autosomal dominant polycystic kidney disease with anticipation and Caroli’s disease associated with a PKD1 mutation. Kidney Int. 52, 33–38 (1997).
Mamone, G. et al. Magnetic resonance imaging of fibropolycystic liver disease: the spectrum of ductal plate malformations. Abdom. Radiol. (NY). 44, 2156–2171 (2019).
Xu, A. M., Xian, Z. H., Zhang, S. H. & Chen, X. F. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature. Eur. J. Gastroenterol. Hepatol. 21, 580–584 (2009).
Lai, Q. & Lerut, J. Proposal for an algorithm for liver transplantation in Caroli’s disease and syndrome: Putting an uncommon effort into a common task. Clin. Transplant. 30, 3–9 (2016).
Petrick, J. L. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. PLoS One 12, e0186643 (2017).
Del Barrio, M., Díaz-González, Á. & Alonso-Peña, M. Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid Metabolism in Disease Progression. Int. J. Mol. Sci. 26 (16), 7905 (2025).
Lendoire, J. C. et al. Caroli’s disease: a report on surgical options and long-term outcomes of patients treated in Argentina: multicenter study. J. Gastrointest. Surg. 15, 1814–1819 (2011).
Fahrner, R., Dennler, S. G. & Inderbitzin, D. Risk of malignancy in Caroli disease and syndrome: A systematic review. World J. Gastroenterol. 26, 4718–4728 (2020).
Coelho, R. et al. CA 19 – 9 as a marker of survival and a predictor of metastasis in cholangiocarcinoma. GE Port J. Gastroenterol. 24, 114–121 (2017).
Tzoufi, M. et al. Caroli’s disease: description of a case with a benign clinical course. Ann. Gastroenterol. 24, 129–133 (2011).
Raut, A., Shrestha, S., Homagain, S., Jayswal, A. & Ghimire, B. Portal hypertension: An uncommon presentation of Caroli’s syndrome. Clin. Case Rep. 8, 3133–3137 (2020).
Taylor, A. C. & Palmer, K. R. Caroli’s disease. Eur. J. Gastroenterol. Hepatol. 10, 105–108 (1998).
Masyuk, T. V., Masyuk, A. I., Torres, V. E., Harris, P. C. & Larusso, N. F. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 132, 1104–1116 (2007).
Yoshihara, D. et al. PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am. J. Physiol. Renal Physiol. 300, F465–F474 (2011).
